NCX-1000, a nitric oxide-releasing derivative of UDCA, does not decrease portal pressure in patients with cirrhosis: results of a randomized, double-blind, dose-escalating study

Berzigotti, Annalisa; Bellot, Pau; De Gottardi, Andrea; Garcia-Pagan, Juan Carlos; Gagnon, Caroline; Spénard, Jean; Bosch, Jaime (2010). NCX-1000, a nitric oxide-releasing derivative of UDCA, does not decrease portal pressure in patients with cirrhosis: results of a randomized, double-blind, dose-escalating study. American journal of gastroenterology, 105(5), pp. 1094-101. New York, N.Y.: Nature 10.1038/ajg.2009.661

Full text not available from this repository.

NCX-1000 (2(acetyloxy) benzoic acid-3(nitrooxymethyl)phenyl ester) is an nitric oxide (NO)-releasing derivative of ursodeoxycholic acid (UDCA), which showed selective vasodilatory effect on intrahepatic circulation in animal models of cirrhosis. This study was aimed at testing the efficacy and tolerability of this compound in patients with cirrhosis and portal hypertension.

Item Type:	Journal Article (Original Article)
Division/Institute:	04 Faculty of Medicine > Service Sector > Institute of Clinical Pharmacology and Visceral Research [discontinued]
UniBE Contributor:	De Gottardi, Andrea
ISSN:	0002-9270
Publisher:	Nature
Language:	English
Submitter:	Factscience Import
Date Deposited:	04 Oct 2013 14:07
Last Modified:	05 Dec 2022 14:00
Publisher DOI:	10.1038/ajg.2009.661
PubMed ID:	19920806
Web of Science ID:	000277440100017
URI:	https://boris.unibe.ch/id/eprint/94 (FactScience: 195741)